The death rate of breast cancer has been decreasing since 1989 because of earlier diagnosis and improved therapy; however, there is no specific target therapy for estrogen receptor-negative, progesterone receptor-negative, and HER2-negative, i.e., triple-negative breast cancer (TNBC). The gene discussed is ERBB2; the disease is breast carcinoma.